On the stock market since 2022, it operates in the world of health and science. It has 24,480 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (4% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 28% below its peak. The market has trimmed its expectations for the company.
The company sells $3.2B a year; the problem isn’t sales — it’s costs running above that number.
It pays out $3.50 per share each year — regular cash for whoever holds the stock.
A loss of $262.7M against $3.2B in annual sales.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, BKDT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BKDT has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.